R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, announced the presentation of a trial-in-progress poster highlighting its ongoing global Phase 2b study of AP306 at the American Society of Nephrology (ASN) Kidney Week 2026, […]
New guide brings together events taking place around the Jefferies Global Healthcare Conference and London Life Sciences Week Helps attendees discover networking opportunities and plan their week from 15 – 20 November 2026 Optimum and Catalyst will bring the community together for a London Landmarks 5K Run on 17 November  London, UK, 13 October […]
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease Neuraxpharm Group announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, […]
Advanced Medical Solutions Group announced its unaudited interim results for the six months ended 30 June 2026 Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2026. Group revenue increased by 4% to £115.5 million and by 3% at […]
New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities On Friday, Quantum Foundry Copenhagen and the Novo Nordisk Foundation announced plans to establish a new 5,300 m² quantum chip fabrication facility in Copenhagen. The facility will develop and scale the advanced manufacturing equipment needed to produce the next generation of quantum chips and strengthen Europe’s […]
